Arrhythmic events associated with immune checkpoint inhibitors therapy: A real‐world study based on the Food and Drug Administration Adverse Event Reporting System database. (24th November 2022)

• Record Type: Journal Article
• Authors: Liu, Yunwei; Chen, Yanxin; Zeng, Zhimin; Liu, Anwen
• Is Part Of: Cancer medicine. Volume 12:Number 6(2023)
• Page Start: 6637
• Page End: 6648
• Publication Date: 2022-11-24
• Subjects: adverse drug events -- arrhythmic events -- data mining -- FAERS -- immune checkpoint inhibitors; 616.994005
• DOI: 10.1002/cam4.5438
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Background: Although arrhythmias have been reported in patients treated with immune checkpoint inhibitors (ICIs), the association between arrhythmias and ICIs has not been thoroughly evaluated in real‐world studies. We aimed to describe the major features of ICI‐related arrhythmic events and identify the factors that contributed to death. Methods: A disproportionality analysis was performed using data from the Food and Drug Administration Adverse Event Reporting System (FAERS) database from January 2011 to December 2021. Reporting odds ratios (RORs), proportional reporting ratio and information component were used to assess whether adverse arrhythmic events were associated with ICIs. The clinical characteristics of patients with ICI‐associated arrhythmias were compared with fatal and non‐fatal arrhythmias. The time to onset (TTO), fatality rates of arrhythmic events were also investigated. Results: We identified a total of 1945 cases of ICI‐related arrhythmic events. Men (64.78%) were identified significantly more frequently than women (28.84%). The median age was 68 years ([interquartile range, IQR] 60–75 years). Anti‐programmed cell death‐1 (PD‐1) and anti‐programmed cell death ligand‐1 (PD‐L1) were associated with adverse arrhythmic events, corresponding to ROR 1.11 (95% confidence interval [CI] 1.05–1.17) and ROR 1.34 (95% CI 1.20–1.49), respectively. However, anti‐cytotoxic T‐lymphocyte associated protein 4 or combination immunotherapy did not appear to be associated with arrhythmic events. Atrial fibrillation ( N = 576, 0.62%), cardiac arrest ( N = 284, 0.31%), tachycardia ( N = 175, 0.19%) were the most common adverse arrhythmic events. Sudden death and complete atrioventricular block are adverse events that are significantly associated with ICI‐related arrhythmic events and have strong signal intensity. The TTO of cases that resulted in death (30 days [IQR] 11–73.75) was significantly earlier than that of cases that did not result in death (33 days [IQR 10.5–88.5], p = 0.003). ICI‐related arrhythmic events were severe with death occurring in 507 (26.07%) of 1945 arrhythmias cases. Conclusions: Treatment with PD‐1/PD‐L1 may cause arrhythmic events, which are severe and tend to occur early on during treatment. It is important to identify ICI‐related arrhythmias as early as possible, and to manage them appropriately. Abstract : This is the largest and most comprehensive pharmacovigilance study until recently to compare the clinical features, associations, timing and prognosis of ICIs‐related arrhythmic events in the real‐world study based on the Food and Drug Administration Adverse Event Reporting System (FAERS) database. Our study shows anti‐PD‐1/PD‐L1 monotherapy may cause arrhythmic events, which are severe and tend to occur early on during treatment. It is important to identify ICI‐related arrhythmias as early as possible, and to manage them appropriately.